Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: An NRG Oncology and Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 33, Issue 36, 2015, Pages 4301-4308

  Goodfellow, Paul J ^a   Billingsley, Caroline C ^a   Lankes, Heather A ^c   Ali, Shamshad ^c   Cohn, David E ^a   Broaddus, Russell J ^f   Ramirez, Nilsa ^b   Pritchard, Colin C ^g   Hampel, Heather ^a   Chassen, Alexis S ^a   Simmons, Luke V ^a   Schmidt, Amy P ^h   Gao, Feng ^h   Brinton, Louise A ⁱ   Backes, Floor ^a   Landrum, Lisa M ^j   Geller, Melissa A ^k   DiSilvestro, Paul A ^l   Pearl, Michael L ^e   Lele, Shashikant B ^d   Powell, Matthew A ^h   Zaino, Richard J ^m   Mutch, David ^h   more..

^a OHIO STATE UNIVERSITY   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NRG Oncology Statistics and Data Management Center   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l WOMEN AND INFANTS HOSPITAL   (United States)

^m PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; PROTEIN MLH1; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; DNA LIGASE; G-T MISMATCH-BINDING PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CANCER FAMILY; DNA METHYLATION ASSAY; ENDOMETRIUM CANCER; EPIGENETICS; FAMILY HISTORY; FEMALE; GENE MUTATION; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; SCREENING; ADULT; AGE; AGED; CHEMISTRY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPARATIVE STUDY; DNA METHYLATION; EARLY CANCER DIAGNOSIS; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; HEALTH SURVEY; MIDDLE AGED; MISMATCH REPAIR; PATHOLOGY; PEDIGREE; PREDICTIVE VALUE; PROCEDURES; STANDARDS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGE FACTORS; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR ENDONUCLEASE PMS2; MUTL PROTEIN HOMOLOG 1; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PEDIGREE; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS;

EID: 84957553878     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.9518     Document Type: Article

References (36)

1. Ollikainen M, Abdel-Rahman WM, Moisio AL, et al: Molecular analysis of familial endometrial carcinoma: A manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 23:4609-4616, 2005
2. Hampel H, Frankel W, Panescu J, et al: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810-7817, 2006
3. Goodfellow PJ, Buttin BM, Herzog TJ, et al: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA100:5908-5913, 2003
4. Egoavil C, Alenda C, Castillejo A, et al: Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One 8:e79737, 2013
5. Ferguson SE, Aronson M, Pollett A, et al: Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120:3932-3939, 2014
6. Lynch HT, Snyder CL, Shaw TG, et al: Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 15:181-941, 2015
7. Baglietto L, Lindor NM, Dowty JG, et al: Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102:193-201, 2010
8. Vasen HF, Abdirahman M, Brohet R, et al: One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300-2306, 2010
9. Lu KH, Daniels M: Endometrial and ovarian cancer in women with Lynch syndrome: Update in screening and prevention. Fam Cancer 12:273-277, 2013
10. Stoffel EM, Mangu PB, Gruber SB, et al: Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer - European Society for Medical Oncology clinical practice guidelines. J Clin Oncol 33:209-217, 2015
11. Lancaster JM, Powell CB, Chen LM, et al: Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 136:3-7, 2015
12. Buchanan DD, Tan YY, Walsh MD, et al: Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32:90-100, 2014
13. Lu KH, Ring KL: One size may not fit all: The debate of universal tumor testing for Lynch syndrome. Gynecol Oncol 137:2-3, 2015
14. Brinton LA, Felix AS, McMeekin DS, et al: Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 129:277-284, 2013
15. Zighelboim I, Schmidt AP, Gao F, et al: ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol 27:3091-3096, 2009
16. Dewdney SB, Rimel BJ, Thaker PH, et al: Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res 17:2120-2129, 2011
17. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
18. Whitcomb BP, Mutch DG, Herzog TJ, et al: Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9:2277-2287, 2003
19. Djordjevic B, Barkoh BA, Luthra R, et al: Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: Retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol 26:1401-1412, 2013
20. Bruegl AS, Djordjevic B, Batte B, et al: Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila) 7:686-697, 2014
21. Pritchard CC, Smith C, Salipante SJ, et al: ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 14:357-366, 2012
22. Kastrinos F, Steyerberg EW, Mercado R, et al: The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73-81, 2011
23. Leenen CH, van Lier MG, van Doorn HC, et al: Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125:414-420, 2012
24. Clendenning M, Senter L, Hampel H, et al: A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. J Med Genet 45:340-345, 2008
25. Truninger K, Menigatti M, Luz J, et al: Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 128:1160-1171, 2005
26. ten Broeke SW, Brohet RM, Tops CM, et al: Lynch syndrome caused by germline PMS2 mutations: Delineating the cancer risk. J Clin Oncol 33:319-325, 2015
27. Lu KH, Dinh M, Kohlmann W, et al: Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569-574, 2005
28. Cook LS, Nelson HE, Stidley CA, et al: Endometrial cancer and a family history of cancer. Gynecol Oncol 130:334-339, 2013
29. Bharati R, Jenkins MA, Lindor NM, et al: Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? Gynecol Oncol 133:287-292, 2014
30. Backes FJ, Hampel H, Backes KA, et al: Are prediction models for Lynch syndrome valid for probands with endometrial cancer? Fam Cancer 8:483-487, 2009
31. Barzi A, Sadeghi S, Kattan MW, et al: Comparative effectiveness of screening strategies for lynch syndrome. J Natl Cancer Inst 20:107, 2015
32. Tan YY, McGaughran J, Ferguson K, et al: Improving identification of lynch syndrome patients: A comparison of research data with clinical records. Int J Cancer 132:2876-2883, 2013
33. Mercado RC, Hampel H, Kastrinos F, et al: Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 14:670-680, 2012
34. Gould-Suarez M, El-Serag HB, Musher B, et al: Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. Dig Dis Sci 59:2913-2926, 2014
35. Ward RL, Dobbins T, Lindor NM, et al: Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry. Genet Med 15:25-35, 2013
36. Pineda M, Mur P, Iniesta MD, et al: MLH1 methylation screening is effective in identifying epimutation carriers. Eur J Hum Genet 20:1256-1264, 2012